FDA Announces Approval of Guidance on Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products

Summary

The Food and Drug Administration (FDA) has announced that it has received approval from the Office of Management and Budget (OMB) to collect information on postmarketing adverse event reporting for nonprescription human drug products marketed without an approved application, as outlined in the newly approved guidance document.